Our own Jared Gollob, M.D., Senior Director of Clinical Research at Alnylam led the discussion, highlighting the important results from our Phase IIa lung transplant study with ALN-RSV01.  We were pleased to report data from this study, demonstrating for the first time the safety and tolerability of inhaled ALN-RSV01 in naturally infected patients with respiratory syncytial virus, or RSV.  Please click on the link below to access a replay of this event.